Jonathan Olefson - Syneos Health General Counsel, Corporate Secretary
| SYNHDelisted Stock | USD 42.31 0.07 0.17% |
Executive
Mr. Jonathan Olefson J.D. is General Counsel, Corporationrationrate Secretary of the Company. Prior to joining Syneos Health, Mr. Olefson was Senior Vice President, General Counsel and Secretary at Cotiviti Holdings, Inc., a healthcare analytics firm, from October 2013 to October 2018. Prior to that, Mr. Olefson spent nine years in senior legal and compliance roles at Cognizant Technology Solutions, a multinational information technology and consulting services firm, most recently as Vice President and General Counsel since 2018.
| Age | 47 |
| Tenure | 6 years |
| Phone | 919 876 9300 |
| Web | https://www.syneoshealth.com |
Syneos Health Management Efficiency
The company has return on total asset (ROA) of 0.0263 % which means that it generated a profit of $0.0263 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0209 %, meaning that it created $0.0209 on every $100 dollars invested by stockholders. Syneos Health's management efficiency ratios could be used to measure how well Syneos Health manages its routine affairs as well as how well it operates its assets and liabilities.Syneos Health currently holds 2.9 B in liabilities with Debt to Equity (D/E) ratio of 0.93, which is about average as compared to similar companies. Syneos Health has a current ratio of 1.08, suggesting that it may have difficulties to pay its financial obligations when due. Note, when we think about Syneos Health's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jonas Greutert | Mettler Toledo International | N/A | |
| Toralf Haag | Qiagen NV | 54 | |
| Stephany Foster | Qiagen NV | 45 | |
| Alistair Grenfell | IQVIA Holdings | N/A | |
| Amy Rocklin | Neogen | 52 | |
| Ross Levine | Qiagen NV | 49 | |
| Elizabeth Tallett | Qiagen NV | 71 | |
| Jon Jacobsen | Aclaris Therapeutics | N/A | |
| Mark Mintz | Charles River Laboratories | N/A | |
| Jim Berkshire | IQVIA Holdings | N/A | |
| Scott Gleason | Myriad Genetics | 45 | |
| Matthew JD | Aclaris Therapeutics | N/A | |
| MD MBA | Aclaris Therapeutics | N/A | |
| Gail MD | Aclaris Therapeutics | 61 | |
| Marc Gueronniere | Mettler Toledo International | 60 | |
| Christine Gordon | RadNet Inc | 61 | |
| Sarah Demey | Neogen | N/A | |
| Robert Pringle | Laboratory of | N/A | |
| Samraat Raha | Myriad Genetics | 51 | |
| Jonathan DiVincenzo | Laboratory of | 58 | |
| Gary Curtis | ICON PLC | N/A | |
Management Performance
| Return On Equity | 0.0209 | |||
| Return On Asset | 0.0263 |
Syneos Health Leadership Team
Elected by the shareholders, the Syneos Health's board of directors comprises two types of representatives: Syneos Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Syneos. The board's role is to monitor Syneos Health's management team and ensure that shareholders' interests are well served. Syneos Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Syneos Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason Meggs, Interim CFO, Executive Vice President | ||
| Jonathan Olefson, General Counsel, Corporate Secretary | ||
| Michael Brooks, Chief Officer | ||
| Judith MD, Chief Officer | ||
| Alistair Macdonald, CEO, Director | ||
| Ronnie Speight, Vice President Investor Relations | ||
| Baba Shetty, Pres Solutions | ||
| Michelle Keefe, CEO Director | ||
| Larry Pickett, Chief Officer | ||
| Donna Kralowetz, Sr Officer |
Syneos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Syneos Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0209 | |||
| Return On Asset | 0.0263 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 7.23 B | |||
| Shares Outstanding | 103.72 M | |||
| Shares Owned By Insiders | 0.48 % | |||
| Shares Owned By Institutions | 94.74 % | |||
| Number Of Shares Shorted | 6.76 M | |||
| Price To Earning | 18.05 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Syneos Stock
If you are still planning to invest in Syneos Health check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Syneos Health's history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |